Comparative Pharmacology
Head-to-head clinical analysis: CIBINQO versus RUXOLITINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIBINQO versus RUXOLITINIB.
CIBINQO vs Ruxolitinib
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIBINQO (abrocitinib) is a Janus kinase (JAK) inhibitor. It selectively inhibits JAK1, which modulates cytokine signaling involved in inflammatory pathways, including interleukin (IL)-4, IL-13, IL-31, and interferon-gamma, reducing the inflammatory response in atopic dermatitis.
Selective inhibitor of Janus-associated kinases (JAK) JAK1 and JAK2, reducing cytokine signaling and hematopoiesis.
100 mg orally once daily, with or without food.
Myelofibrosis: 5-25 mg orally twice daily based on platelet count; Polycythemia Vera: 10 mg orally twice daily; Graft-versus-Host Disease: 5-10 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours in healthy subjects, supporting twice-daily dosing. No significant accumulation after multiple doses.
Clinical Note
moderateRuxolitinib + Digoxin
"Ruxolitinib may increase the bradycardic activities of Digoxin."
Clinical Note
moderateRuxolitinib + Digitoxin
"Ruxolitinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateRuxolitinib + Deslanoside
"Ruxolitinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateRuxolitinib + Acetyldigitoxin
"Ruxolitinib may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life of ruxolitinib is approximately 3 hours for the parent drug. However, the pharmacodynamic half-life for JAK2 inhibition is longer (up to 8-12 hours) due to sustained target suppression.
Primarily excreted via feces (69%) and urine (20%) after oral administration. Renal elimination accounts for <1% of unchanged drug. Biliary excretion is the major route for metabolites.
Ruxolitinib is primarily metabolized in the liver, and its metabolites are excreted renally. Approximately 74% of the dose is eliminated in urine (mainly as metabolites) and 22% in feces (as unchanged drug and metabolites).
Category C
Category D/X
JAK Inhibitor
JAK Inhibitor